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Objective: Ventilator associated pneumonia (VAP) has been shown to be associated with signiﬁcant
morbidity and mortality (Chastre and Fagon, 2002; Klompas, 2007) among mechanically ventilated
patients in the intensive care unit (ICU), with the incidence ranging from 9% to 27%; crude mortality
ranges from 25% to 50% (Rello, Ollendorf, Oster, et al., 2002; Tablan, Anderson, Besser, Bridges, Hajjeh,
2003). A meta-analysis of published studies was undertaken to combine information regarding the effect
of subglottic secretion drainage (SSD) on the incidence of ventilated associated pneumonia in adult ICU
patients.
Methods: Reports of studies on SSD were identiﬁed by searching the PUBMED, EMBASE, and
COCHRANCE LIBRARY databases (December 30, 2010). Randomized trials of SSD compared to usual care
in adult mechanically ventilated ICU patients were included in this meta-analysis.
Results: Ten RCTs with 2314 patients were identiﬁed. SSD signiﬁcantly reduced the incidence of VAP
(relative risk [RR] ¼ 0.52, 95% conﬁdence interval [CI]: 0.42e0.64, p < 0.00001). When SSD was compared
with the control groups, the overall RR for ICU mortality was 1.00 (95% CI, 0.84e1.19) and for hospital
mortality was 0.95 (95% CI, 0.80e1.13). Overall, the subglottic drainage effect on the days of mechanical
ventilation was 1.52 days (95% CI, 2.94 to 0.11) and on the ICU length of stay (LOS) was 0.81days
(95% CI, 2.33 to e0.7).
Conclusions: In this meta-analysis, when an endotracheal tube (ETT) with SSD was compared with an
ETT without SSD, there was a highly signiﬁcant reduction in the VAP rate of approximately 50%. Time on
mechanical ventilation (MV) and the ICU LOS may be reduced, but no reduction in ICU or hospital
mortality has been observed in published trials.
© 2015 Shanxi Medical Periodical Press. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Patients who require invasive mechanical ventilation (MV) are
at risk for ventilator-associated pneumonia (VAP).1 It has been
shown to be associated with signiﬁcant morbidity and mortality2,3
among mechanically ventilated patients in the intensive care unit
(ICU). It also has been proved to be associated with prolonged
durations of MV, ICU stay and hospital stay, in addition to increased
healthcare costs.4,5 For all of these reasons, the prevention of VAP
has been important in ICU clinician research.Yang).
al Periodical Press.
to this study.
Production and hosting by ElsevColonization of the upper respiratory tract (oropharaynx and
trachea) secretions with potentially pathogenic organisms has been
recognized as being a key factor in the pathogenesis of VAP.2,3
These secretions have been shown to pool above the cuff of
endotracheal tubes (ETT) prior to entering the lower respiratory
tract as micro-aspirations.6 Therefore, subglottic secretion drainage
(SSD) with a specialized ETT that incorporates a suction port above
the cuff has been proposed and tested as a method to attempt to
reduce the incidence of VAP in ICU patients.7
Since the introduction of SSD into medical practice, many
studies have examined the efﬁcacy and effectiveness of SSD in
preventing VAP.8 It is necessary to update the studies to provide
more solid evidence and to minimize the potential bias that is
caused by limited publications. Thus, we performed an updated
meta-analysis to investigate the results of published SSD trials and
the effect of SSD on the incidence of VAP, ICU and hospital mor-
tality, ICU length of stay (LOS), and duration of MV.ier B.V. This is an open access article under the CC BY-NC-ND license (http://
R. Wang et al. / Chinese Nursing Research 2 (2015) 55e60562. Materials and methods
2.1. Search strategy
We followed the PRISMA guideline for reporting our meta-
analysis.9 Related articles that were published in English or Chinese
were identiﬁed and selected by searching PUBMED, EMBASE,
CINAHL and the Cochrane Central Register of Controlled Trials
(December 31, 2013). All of the bibliographies were also identiﬁed
in the reference lists. Search strategies were adapted for all data-
bases, and the following search terms were used: (1) glottis or
suction or drainage and respiration, and (2) artiﬁcial or ventilation
or intubation, and (3) mechanical, and (4) pneumonia.
2.2. Study selection criteria
All of the potential studies were retrieved and reviewed. We
included studies if they: (1) were randomized controlled studies
(RCTs), (2) studied adult critically ill patients who required invasive
MV, (3) included ETTs with SSD in an experimental group
compared to standard ETTs in a control group, and (4) reported on
the incidence of VAP as deﬁned by the investigators. Pregnant or
lactating women and patients who were children were excluded.
2.3. Data extraction
Two reviewers independently extracted the following data: ﬁrst
author's surname, year of publication, setting of trials, number of
participants in studies, method of subglottic drainage (intermittent
or continuous and frequency), and deﬁnition of VAP and other in-
terventions. The quality of trials was assessed with the method
recommended by the Cochrane Collaboration for assessing the bias
risk.10
2.4. Data synthesis and analysis
All of the data that were extracted were entered in the freeware
program Review Manager (RevMan) Version 5.2 (Copenhagen: The
Nordic Cochrane Centre, The Cochrane Collaboration, 2012). Dif-
ferences were expressed as relative risks (RRs) with 95% conﬁdence
intervals (95% CIs) for dichotomous outcomes. Binary outcomes
(i.e., VAP and mortality) are reported as ManteleHaenszel style risk
ratios (RRs), whereas continuous outcomes are reported as inverse
variance weightedmean differences. A ﬁxed-effect model was used
in cases of homogeneity (p value of c2 test >0.10 and I2  50%), and
a random-effects model was used in cases of signiﬁcant heteroge-
neity (p value of c2 test >0.10 and I2 >50%). Publication bias was
assessed by the inspection of funnel plots, and asymmetry was
assessed using the regression test suggested by Egger (a p-value
<0.1 was considered to be evidence of funnel plot asymmetry).11
3. Results
From our search strategy, a total of 146 potential studies were
selected for secondary review after excluding non-randomized
trials and review articles; twelve published randomized trials
were included in the analysis,12,23 but 2 studies12,13 were excluded
because the interventions might have inﬂuenced the effectiveness
of SSD in reducing VAP and were therefore ineligible. We reviewed
and abstracted data from each study prior to discussing the results
(Table 1 and Table 2).
The included studies, with a randomized total of 2314 patients,
are summarized in Table 1. The main inclusion criterion was
predicated on the duration of expected MV in 9 of the 10 studies:
one study18 had an expected duration of MV > 24 h, fourstudies15,17,22,23 had an expected duration of MV > 48 h, and four
studies4,19e21 had an expected duration of MV > 72 h. In all of the
studies, ETTs with SSD were placed at the time of original intuba-
tion. The deﬁnitions of VAP always included radiologic criteria (new
or persistent inﬁltrates on a chest radiograph) along with clinical
and microbiological criteria.24 The methods used to drain the
subglottic secretion ranged from intermittent aspiration with a
syringe to continuous suction (Table 1).
The pooled analyses across studies are graphically expressed in
Figs. 1 to 5. The vertical line in the centre indicates that the esti-
mated effects are the same for both the intervention and control
groups and is often called the line of no difference. The values on
the left of the line favour SSD, and those on the right favour the
control. The diamond on the lower aspect of the graph near the
horizontal line represents pooled values.25
In the meta-analysis for the primary outcome, the overall risk
ratio (RR) for VAP was 0.52 (95% CI: 0.42e0.64; p < 0.00001), with
no heterogeneity (I2 ¼ 0%) (Fig. 1). It showed that SSD signiﬁcantly
reduced the incidence of VAP. Nine studies reported on mortality
(either ICU or hospital); seven reported on ICU LOS. There was no
effect on mortality in either the ICU (RR, 1.00; 95% CI, 0.84e1.19;
p ¼ 0.91) or the hospital (RR, 0.95; 95% CI, 0.80e1.13; p ¼ 0.98)
(Figs. 2 and 3, respectively). There was a signiﬁcant reduction of
1.52 days in the duration of ICU LOS (95% CI, 2.94 to 0.11;
p ¼ 0.03), although there was signiﬁcant heterogeneity (I2 ¼ 77%)
When the study by Kollef and colleagues17 was removed, I2 ¼ 4%
with z ¼ 5.83, P < 0.00001, which indicated adequate homogeneity
for pooling the study results. The mean ICU stay length was 2.29
days shorter than that in the group that received subglottic
drainage (Fig. 4). Six studies reporting on the MV duration were
able to be aggregated, and in these, MV durationwas reduced (0.81
days; 95% CI, 2.33e0.7; p ¼ 0.29), although there was signiﬁcant
heterogeneity (I2 ¼ 94%) (Fig. 5).
Moreover, two studies reported antibiotic utilization. Bouza
et al15 reported a reduction in the number of deﬁned daily doses of
antibiotics with SSD (1213 vs.1932; p < 0.001), whereas Lacherade
et al17 did not ﬁnd any difference in antibiotic utilization. Addi-
tionally, the re-intubation rates were also available in three studies:
Kollef et al16 reported re-intubation rates of ﬁve out of 160 (3.1%)
patients in the SSD group and six out of 183 (3.3%) patients in the
control group, Bouza et al15 reported that re-intubation rates were
12 out of 331 (3.6%) patients in the SSD group and 14 out of 359
(3.9%) patients in the control group, and Lacherade et al17 reported
re-intubation rates of 21 out of 169 (1.2%) patients in the SSD group
and 20 out of 164 (1.2%) in the control group.
4. Discussion
The goal of this study was to examine the effectiveness of sub-
glottic secretion aspiration in reducing the occurrence of VAP. In
this meta-analysis, when an ETT with SSD was compared with an
ETT without SSD, there was a highly signiﬁcant reduction in the
VAP rate of approximately 50% (RR ¼ 0.52, 95% CI 0.42e0.64) and a
reduction in the number of MV patients. No reduction in the risk of
ICU or hospital mortality was observed in our study, although this
may not be surprising given that adequately treated VAP may
demonstrate little or no attributable mortality.24 Although only a
slight reduction in duration of MV (summary estimate nearly 1
days, 95% CI, 2.33 to 0.7) and ICU LOS (about 1.5 days, 95%
CI, 2.94 to 0.11) was observed, signiﬁcant variation existed
among studies that were included in the meta-analysis. Although
the number of RCTs increased to 10 and the number of randomized
patients was over 2300, our ﬁndings are similar to those of a pre-
vious smaller meta-analysis that found a 50% reduction in VAP, but
no beneﬁt in reducing ICU or hospital mortality; the number of
Table 1
Characteristics of the included trials.
Author, year
(reference)
Setting and patients Intervention (I) and control (C) Exclusion criteria Deﬁnition of VAP Findings
Bo, 200014 Surgical ICU, 68 patients
expected to require MV > 72 h
I ¼ SSD with continuous
aspiration of secretion
C ¼ conventional ETT
None reported Clinical features or
positive blood/pleural
cultures
The morbidity of VAP in MV can
be reduced by SSD, especially
for VAP caused by Gram-
positive cocci and Haemophilus
inﬂuence organisms.
Bouza, 200815 Single Cardiothoracic ICU in
Spain. Between May 2004 and
July 2006,714 patients who had
received MV > 48 h were
included.
I ¼ SSD with continuous
aspiration of secretions,
C ¼ conventional ETT
Culture of protected
telescoping catheter
sample or
bronchoalveolar lavage
ﬂuid following clinical
suspicion
SSD is a safe procedure that
reduces the use of antimicrobial
agents in the overall population
and the incidence of VAP in
patients who are at risk.
Kollef, 199916 343 cardiac surgery patients
required MV from the
cardiothoracic ICU at Barnes
Jewish Hospital in St Louis
I ¼ SSD with continuous low
intermittent suction >20
cmH2O
C ¼ SSD without suction
Patients who were
transferred from an
outside hospital or had
already received MV
before the study.
Clinical features,
positive tracheal or
blood or pleural
cultures, radiographic
abscess, or positive
histology
SSD can be safely administered
to patients undergoing cardiac
surgery. The occurrence of VAP
can be signiﬁcantly delayed
among patients undergoing
cardiac surgery using SSD.
Lacherade, 201017 333 patients expected to
require MV  48 h who from
Four French Medico surgical
ICUs
I ¼ SSD, intermittent secretion
drainage every 1 h with a 10-ml
syringe,
C ¼ Hi-Lo ETT
Patients admitted in
ICUs with prior
tracheostomy or
already intubated with
a tube other than the
Hi-Lo Evac tube
Quantitative culture of
protected telescoping
catheter sample or
bronchoalveolar lavage
ﬂuid following clinical
suspicion
SSD during MV results in a
signiﬁcant reduction in VAP,
including late-onset VAP.
Lorente, 200718 Between March 1,2006 and
October 31,2006, 280 patients
who expected to require
MV  24 h were included in a
single medicalesurgical ICU in
Spain
I ¼ SSD, intermittent secretion
drainage every 1 h with a 10-ml
syringe,
C ¼ conventional ETT
Age less than 18 years,
pregnancy, infection
with HIV, blood
leukocyte count less
than 1000 cells/mm3,
solid or haematological
tumour, and/or
immunosuppressive
therapy.
Clinical features and
signiﬁcant quantitative
culture via ETT
aspiration.
The use of an endotracheal tube
with polyurethane cuff and
subglottic secretion drainage
helps prevent early and late-
onset VAP.
Mahul, 199219 Medical-surgical ICU, 145
patients expected to require
MV > 72 h.
I ¼ SSD intermittent secretion
drainage every 1 h with a 10-ml
syringe C ¼ conventional ETT
Positive
bronchoalveolar lavage
culture required
SSD treatment was associated
with a twice lower incidence of
NP, and a prolonged time of
onset of NP but a decrease in
the colonization rate from
admission to end-point day in
tracheal aspirates and in
subglottic secretions
Smulders, 200220 FromMay 1999 to June 2000, in
a 12-Bed general ICU, 150
patients with an expected
MV > 72 h were enrolled
I ¼ SSD intermittent 20-s
intervals,8-s duration, 100 mm
Hg suction;
C ¼ standard ETT
Clinical features or
positive blood/pleural
A randomized clinical trial of
intermittent subglottic
secretion drainage in patients
receiving mechanical
ventilation
Valles, 199521 From June 1990 to March
1993,153 patients from a
medical-surgical ICU who were
expected to require MV > 72 h
were enrolled.
I ¼ SSD with continuous low
aspiration suction
>20 cmH2O
C ¼ SSD without suction
intubated in other areas
of the hospital, or
carried a tracheostomy
tube, or developed a
pneumonia or died
during the ﬁrst 72 h of
MV
Clinical features
conﬁrmed with
bronchoscopically
obtained cultures
The incidence of NP in
mechanically ventilated
patients can be signiﬁcantly
reduced by using a simple
method that decreases chronic
micro-aspirations through
continuous aspiration of
subglottic secretions.
Yang, 200822 Between October, 2004 and
April, 2006, 91 patients were
treated with MV > 48 h
I¼SSD with continuous
aspiration suction between 100
and 150 mm Hg
C ¼ conventional ETT
Clinical features and
culture of endotracheal
aspiration
Effective continuous aspiration
of subglottic secretion could
signiﬁcantly reduce the
morbidity of early onset VAP.
Zheng, 200823 From January 2005 to June
2006, 61 patients with an
expected duration of MV > 48 h
and age >18 years were
enrolled.
I ¼ SSD continuous aspiration
suction between 25 and 30
cmH2O C ¼ conventional ETT
If they developed a
pneumonia during the
ﬁrst 72 h or MV < 48 h.
The NNIS system
diagnostic for criteria
for VAP were followed.
Effective SSD is one important
measure that can prevent VAP.
Notes: I, intervention; C, control; VAP, ventilator-associated pneumonia; ICU, intensive care unit; SSD, subglottic secretion drainage; MV, mechanical ventilation; ETT,
endotracheal tubes; NP, nosocomial pneumonia; HIV, human immunodeﬁciency virus.
R. Wang et al. / Chinese Nursing Research 2 (2015) 55e60 57ventilation days were also estimated to be reduced by approxi-
mately 2 days when the intervention and control groups were
compared.7 Muscedere and colleagues26 also published an updated
meta-analysis; the results of this more recent meta-analysis are
also similar to ours.In addition, some complications that are attributed to SSD in the
process of MV were also reported. In this meta-analysis, only three
trials14e16 mentioned the complications related to SSD; two14,15 of
them used continuous SSD, and no complications were observed.
One16 trial with intermittent SSD proved that the incidence of post-
Table 2
Summary of the results of the included trials.
Study VAP ICU mortality Hospital mortality ICU length of stay MV duration
SSD Control SSD Control SSD Control SSD Control SSD Control
Bo 2000 8 15
Bouza,2008 12 19 22 23 23 26 5.6 ± 10.7 6.5 ± 14.2
Kollef,1999 8 15 6 8 3.7 ± 4.6 3.2 ± 4.5 1.5 ± 3.3 1.9 ± 5.1
Lacherade,2010 25 42 71 65 80 84 15.9 ± 14.4 15.7 ± 20.4 8.0 ± 4.0 6.0 ± 4.0
Lorente,2007 11 31 26 32 14.1 ± 17.9 15.5 ± 19.9 10.5 ± 15.91 11.1 ± 15.19
Mahul,1992 9 21 17 16
Smulders,2002 3 12 12 10 9.3 ± 7.4 12.3 ± 3.6 5.8 ± 4.4 7.1 ± 5.4
Valles, 1995 14 25 19.4 ± 4.0 22 ± 2.0 11.0 ± 1.0 13.0 ± 1.0
Yang, 2008 12 20 32 29
Zheng, 2008 9 16 8 12 9.3 ± 2.9 12.3 ± 5.7 7.9 ± 2.6 10.4 ± 0.9
Fig. 1. Rate of ventilator-associated pneumonia between groups with a subglottic secretion and without subglottic secretion.
R. Wang et al. / Chinese Nursing Research 2 (2015) 55e6058extubation events did not differ signiﬁcantly, but safety concerns
regarding SSD still existed.27 In the study by Berra and colleagues,28
all 30 sheep undergoing continuous SSD during the MV period
suffered from different degrees of tracheal mucosal injury. Girou12Fig. 2. Intensive care unit mortality compared between patients receiving endotrachalso reported that approximately 40% of the patients with contin-
uous SSD developed laryngeal oedema after extubation. Therefore,
safety issues associated with SSD should be observed in a more
systematic evaluation in the future.eal tubes with a subglottic secretion drainage and standard endotracheal tubes.
Fig. 3. Hospital mortality compared between patients receiving endotracheal tubes with a subglottic secretion drainage and standard endotracheal tubes.
R. Wang et al. / Chinese Nursing Research 2 (2015) 55e60 59In our meta-analysis, six studies14e16,21e23 used continuous
suction, and the other four studies19e22 used intermittent suction. It
has been reported that both intermittent and continuous SSD
signiﬁcantly reduced the incidence of VAP8; earlier studies were
more likely to use intermittent SSD, whereas more recent studies
utilized continuous aspiration.29 However, no trial was conducted
directly to compare the two methods and whether intermittent
SSD was more effective than continuous SSD was unclear.8 Thus,
more RCTs that are powered to address this issue are warranted in
further studies.Fig. 4. Intensive care unit length of stay compared between patients receiving endotra
Fig. 5. Duration of mechanical ventilation compared between patients receiving endotrBecause no efforts were made to locate either studies with
negative results or unpublished studies, this meta-analysis may be
at risk of publication bias.30 Another potential limitation of this
study may be the signiﬁcant heterogeneity between study pop-
ulations and methods of SSD, deﬁnitions of VAP, and other con-
current measures, which contributes to differing RRs across the
trials. Additionally, the beneﬁt of the drainage of subglottic secre-
tions in preventing VAP appears to increase as the underlying risk
increases in the underlying ICU population.cheal tubes with a subglottic secretion drainage and standard endotracheal tubes.
acheal tubes with a subglottic secretion drainage and standard endotracheal tubes.
R. Wang et al. / Chinese Nursing Research 2 (2015) 55e60605. Conclusions
Our meta-analysis suggested that SSD reduced the incidence of
VAP, shortened ventilation duration, and shortened the length of
ICU stay. However, SSD did not improve ICU or hospital mortality,
even though SSD has been suggested or recommended by several
guidelines to prevent VAP31,32. Further research on methods to
implement ETTs with SSD into practice and the safety issues of SSD
is required.
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